Telesta, BL&H deal

Telesta granted BL&H exclusive rights to commercialize MCNA in South Korea. In June, Telesta submitted a BLA to FDA for the mycobacterial cell wall-DNA complex (MCC) to treat high-risk non-muscle inv...